Literature DB >> 11470555

Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology in Alzheimer's disease.

F García-Sierra1, C M Wischik, C R Harrington, J Luna-Muñoz, R Mena.   

Abstract

Neurofibrillary pathology is a characteristic hallmark of Alzheimer's disease that is closely correlated with cognitive decline. We have analysed the density and distribution of neurofibrillary tangles (NFTs) that are immunoreactive with the monoclonal antibody (mAb) 423 in a prospectively analysed population of Alzheimer's disease (AD) cases and age-matched controls. NFTs were examined in allocortical and isocortical areas and correlated with Braak pathological stage and clinical severity of dementia. The mAb 423 was used as it recognises a C-terminally truncated tau fragment that is a major constituent of NFTs. Our results show that extracellular NFTs and, to a lesser extent, intracellular NFTs, correlated significantly with both Braak stages and the clinical index of severity. Furthermore, a differential distribution of the two types of tangles indicates that layer II of the entorhinal cortex and the transentorhinal area are particularly vulnerable to neurofibrillary degeneration. These areas serve as a point of connection between isocortex and hippocampus. Our findings, therefore, suggest that the perforant pathway may be substantially affected by the accumulation of truncated tau protein in AD and that this represents a neuropathological predictor for the clinical severity of dementia. When neurofibrillary pathology was examined by combined labelling with mAbs 423 and Alz-50 and the dye thiazin red, we were able to demonstrate various stages of tau aggregation. The different stages may represent a sequence of conformational changes that tau proteins undergo during tangle formation in the allocortex during the early development of dementia in AD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470555     DOI: 10.1016/s0891-0618(01)00096-5

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  17 in total

1.  Truncation of tau at E391 promotes early pathologic changes in transgenic mice.

Authors:  Pamela J McMillan; Brian C Kraemer; Linda Robinson; James B Leverenz; Murray Raskind; Gerard Schellenberg
Journal:  J Neuropathol Exp Neurol       Date:  2011-11       Impact factor: 3.685

2.  Cleavage and conformational changes of tau protein follow phosphorylation during Alzheimer's disease.

Authors:  Siddhartha Mondragón-Rodríguez; Gustavo Basurto-Islas; Ismael Santa-Maria; Raúl Mena; Lester I Binder; Jesús Avila; Mark A Smith; George Perry; Francisco García-Sierra
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

3.  Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Authors:  David J Irwin; Todd J Cohen; Murray Grossman; Steven E Arnold; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

Review 4.  Tau Proteins and Tauopathies in Alzheimer's Disease.

Authors:  Fong Ping Chong; Khuen Yen Ng; Rhun Yian Koh; Soi Moi Chye
Journal:  Cell Mol Neurobiol       Date:  2018-01-03       Impact factor: 5.046

5.  Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer's disease.

Authors:  Sanaz Arezoumandan; Sharon X Xie; Katheryn A Q Cousins; Dawn J Mechanic-Hamilton; Claire S Peterson; Camille Y Huang; Daniel T Ohm; Ranjit Ittyerah; Corey T McMillan; David A Wolk; Paul Yushkevich; John Q Trojanowski; Edward B Lee; Murray Grossman; Jeffrey S Phillips; David J Irwin
Journal:  Acta Neuropathol       Date:  2022-07-23       Impact factor: 15.887

6.  Modifications of tau protein after cerebral ischemia and reperfusion in rats are similar to those occurring in Alzheimer's disease - Hyperphosphorylation and cleavage of 4- and 3-repeat tau.

Authors:  Hiroki Fujii; Tetsuya Takahashi; Tomoya Mukai; Shigeru Tanaka; Naohisa Hosomi; Hirofumi Maruyama; Norio Sakai; Masayasu Matsumoto
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

7.  Accumulation of aspartic acid421- and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease.

Authors:  Gustavo Basurto-Islas; Jose Luna-Muñoz; Angela L Guillozet-Bongaarts; Lester I Binder; Raul Mena; Francisco García-Sierra
Journal:  J Neuropathol Exp Neurol       Date:  2008-05       Impact factor: 3.685

8.  The abnormally phosphorylated tau lesion of early Alzheimer's disease.

Authors:  Ramasamy Thangavel; Gary W Van Hoesen; Asgar Zaheer
Journal:  Neurochem Res       Date:  2008-04-25       Impact factor: 3.996

Review 9.  Cytoskeletal pathologies of Alzheimer disease.

Authors:  James R Bamburg; George S Bloom
Journal:  Cell Motil Cytoskeleton       Date:  2009-08

10.  Structure and pathology of tau protein in Alzheimer disease.

Authors:  Michala Kolarova; Francisco García-Sierra; Ales Bartos; Jan Ricny; Daniela Ripova
Journal:  Int J Alzheimers Dis       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.